Incyte

INCYNASDAQ

Small-molecule discovery with hematology and dermatology development expertise

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for INCY yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Commercial.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

AXemplify-357: Axatilimab in Chronic graft-versus-host disease, first line — primary completion

2027-09-28

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

INCB123667 ovarian: INCB123667 in Platinum-resistant ovarian cancer, cyclin E1 overexpression — primary completion

2028-11-15

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

EXCALIBUR-ET2: INCA033989 in CALR-mutant essential thrombocythemia — primary completion

2029-06-15

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
Jakafimyelofibrosis and graft-versus-host diseaseApprovedNot disclosed▼
Povorcitinibhidradenitis suppurativa and vitiligoPhase 3Not disclosed▼
Retifanlimabsquamous cell anal cancer and other tumorsPhase 3Not disclosed▼

Analysis

We have not yet written an analysis of Incyte that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade INCY commission-free on Webullvia Webull · Affiliate

Comparable companies

Blueprint MedicinesAbbVieAmgen

Sponsored

Get premium INCY analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Incyte has 200 Phase 2 or 3 studies on ClinicalTrials.gov: 97 completed, 62 stopped early, 41 ongoing.

97

Completed

62

Stopped early

41

Ongoing

Stopped early

  • NCT06873789Phase 1/2 · started 2025 · terminated

    INCB177054 in solid tumors · n=9

    Reason given: This was a strategic business decision. There were no safety concerns contributing to this decision.

  • NCT05949632Phase 1/2 · started 2024 · terminated

    INCB099280 in advanced solid tumors · n=5

    Reason given: This was a strategic business decision. There were no safety concerns contributing to this decision.

  • NCT05359692Phase 2 · started 2023 · withdrawn

    INCAGN01876 in metastatic head and neck squamous cell carcinoma · n=0

    Reason given: Business decision; no safety concerns

  • TRuE-CHE1Phase 3 · started 2023 · withdrawn

    Ruxolitinib cream in hand eczema · n=0

    Reason given: Business decision; no safety concerns.

  • TRuE-CHE2Phase 3 · started 2023 · withdrawn

    Ruxolitinib cream in chronic hand eczema (che) · n=0

    Reason given: Business decision; no safety concerns

  • NCT04796922Phase 3 · started 2022 · withdrawn

    parsaclisib in follicular lymphoma ( fl) · n=0

    Reason given: This study was withdrawn due to a business decision.

  • FIGHT-209Phase 2 · started 2022 · terminated

    Pemigatinib in glioblastoma · n=83

    Reason given: Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.

  • PATHWAYPhase 3 · started 2022 · terminated

    parsaclisinib in warm autoimmune hemolytic anemia (waiha) · n=13

    Reason given: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

  • CITADEL-310Phase 3 · started 2022 · withdrawn

    parsaclisib in mantle cell lymphoma · n=0

    Reason given: business decision; no enrolled patients

  • OptimusPhase 2 · started 2022 · terminated

    retifanlimab in urothelial carcinoma · n=30

    Reason given: Business Decision. No safety concerns contributed to this decision.

  • topMINDPhase 1/2 · started 2021 · terminated

    tafasitamab in chronic lymphocytic leukemia · n=54

    Reason given: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

  • NCT04629339Phase 2 · started 2021 · terminated

    INCB086550 in non small cell lung cancer · n=16

    Reason given: Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.

  • LIMBERPhase 1/2 · started 2021 · terminated

    INCB000928 in myelodysplastic syndromes · n=22

    Reason given: Strategic Business Decision

  • NCT04949191Phase 2 · started 2021 · terminated

    Pemigatinib in advanced malignancies · n=10

    Reason given: A business decision due to availability of commercial drug and other options for accessing study drug treatment.

  • NCT04551053Phase 3 · started 2021 · terminated

    parsaclisib in myelofibrosis · n=177

    Reason given: The study was terminated due to futility.

  • NCT04551066Phase 3 · started 2021 · terminated

    parsaclisib in myelofibrosis · n=252

    Reason given: The study was terminated due to futility.

  • NCT04640025Phase 2 · started 2021 · terminated

    itacitinib in myelofibrosis · n=18

    Reason given: The decision to close the study was made due to the expiration of remaining drug supply.

  • NCT04203511Phase 3 · started 2020 · withdrawn

    Retifanlimab in non-small cell lung cancer · n=0

    Reason given: Sponsor Strategic/Business Decision

  • NCT04377620Phase 3 · started 2020 · terminated

    Placebo in covid-19 · n=211

    Reason given: Study terminated by sponsor

  • NCT04003610Phase 2 · started 2020 · terminated

    Pemigatinib in metastatic urothelial carcinoma · n=7

    Reason given: The reason this study was terminated was due to a business decision. There were no safety concerns that contributed to this decision.

  • NCT03978637Phase 1/2 · started 2020 · terminated

    Itacitinib in bronchiolitis obliterans syndrome · n=23

    Reason given: Business Decision

  • NCT03721965Phase 1/2 · started 2019 · terminated

    Itacitinib in acute graft-versus-host disease · n=2

    Reason given: The study was terminated due to insufficient efficacy in a separate phase III study

  • NCT04003623Phase 2 · started 2019 · terminated

    Pemigatinib in advanced or metastatic solid tumors · n=1

    Reason given: The study was closed due to lack of enrollment.

  • NCT03822117Phase 2 · started 2019 · terminated

    Pemigatinib in solid tumor malignancy · n=111

    Reason given: A business decision was made to to discontinue further enrollment. There were no safety concerns that contributed to this decision.

  • NCT03837509Phase 1/2 · started 2019 · terminated

    INCB001158 in relapsed or refractory multiple myeloma · n=15

    Reason given: This decision follows recruitment difficulties. No safety-related concerns impacted this decision.

  • FIGHT-302Phase 3 · started 2019 · terminated

    Pemigatinib in unresectable cholangiocarcinoma · n=167

    Reason given: The study was terminated due to lack of enrollment resulting from a change in the standard of care for the first-line treatment of patients with cholangiocarcinoma. There were no safety concerns that contributed to this decision.

  • NCT03780166Phase 2 · started 2019 · withdrawn

    Parsaclisib in pemphigus vulgaris · n=0

    Reason given: The study was withdrawn due to insufficient interest in study participation due to recent approval in this rare condition.

  • NCT03584516Phase 2/3 · started 2019 · terminated

    Itacitinib in chronic graft-versus-host disease · n=155

    Reason given: The study was terminated due to insufficient efficacy to support moving into Part 2 of the study; there were no safety concerns that contributed to this decision.

  • NCT03627052Phase 2 · started 2018 · withdrawn

    Itacitinib in moderate to severe ulcerative colitis · n=0

    Reason given: Study withdrawn due to lack of recruitment. No patients enrolled. No safety concerns.

  • NCT03347123Phase 1/2 · started 2018 · terminated

    Epacadostat in solid tumors · n=11

    Reason given: A business decision made by Incyte after analysis of data from a sister study.

  • NCT03361228Phase 1/2 · started 2018 · terminated

    INCB001158 in solid tumors · n=5

    Reason given: Study was terminated early based on emerging data with epacadostat and pembrolizumab.

  • NCT03348904Phase 3 · started 2017 · terminated

    Nivolumab in lung cancer · n=2

    Reason given: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

  • NCT03342352Phase 3 · started 2017 · withdrawn

    Nivolumab in head and neck cancer · n=0

    Reason given: Study was cancelled prior to enrolling any patients.

  • NCT03277352Phase 1/2 · started 2017 · terminated

    INCAGN01876 in advanced malignancies · n=10

    Reason given: The study was terminated due to emergent data from another study and unrelated to safety.

  • NCT03123588Phase 2 · started 2017 · terminated

    Ruxolitinib in mpn (myeloproliferative neoplasms) · n=12

    Reason given: Enrollment issues

  • NCT02959437Phase 1/2 · started 2017 · terminated

    Azacitidine in solid tumors · n=70

    Reason given: Study terminated by Sponsor

  • NCT02718300Phase 2 · started 2017 · terminated

    Parsaclisib in mpn (myeloproliferative neoplasms) · n=74

    Reason given: A business decision was made to discontinue further enrollment. There were no safety concerns that contributed to this decision.

  • NCT02711137Phase 1/2 · started 2016 · terminated

    INCB057643 in solid tumors · n=137

    Reason given: Study terminated due to safety issues.

  • NCT02712905Phase 1/2 · started 2016 · terminated

    INCB059872 in solid tumors and hematologic malignancy · n=116

    Reason given: Strategic Business Decision

  • NCT02587598Phase 1/2 · started 2015 · terminated

    INCB053914 in solid tumors · n=97

    No reason recorded in the registry.

  • NCT02553330Phase 2 · started 2015 · terminated

    Placebo Cream in alopecia areata · n=90

    Reason given: The study was terminated early based on the results of a planned interim analysis.

  • NCT02456675Phase 2 · started 2015 · terminated

    INCB040093 Monotherapy in refractory hodgkin lymphoma · n=8

    Reason given: A decision was made to terminate the study due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma.

  • NCT02431260Phase 1/2 · started 2015 · terminated

    INCB054329 Monotherapy in solid tumors and hematologic malignancy · n=69

    Reason given: As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.

  • NCT02393248Phase 1/2 · started 2015 · terminated

    Pemigatinib in lung cancer · n=201

    No reason recorded in the registry.

  • NCT02355431Phase 2 · started 2014 · withdrawn

    Itacitinib in solid tumors and hematologic malignancy · n=0

    Reason given: Study withdrawn before enrolling first patient

  • NCT02257619Phase 2 · started 2014 · terminated

    Itacitinib in nsclc (non-small cell lung carcinoma) · n=9

    Reason given: Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.

  • NCT02265510Phase 1/2 · started 2014 · terminated

    INCB052793 in solid tumors · n=83

    No reason recorded in the registry.

  • NCT02119663Phase 3 · started 2014 · terminated

    Ruxolitinib in pancreatic cancer · n=86

    Reason given: The safety committee found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.

  • NCT02151474Phase 2 · started 2014 · terminated

    INCB047986 in rheumatoid arthritis · n=3

    Reason given: Business decision.

  • NCT02120417Phase 2 · started 2014 · terminated

    Ruxolitinib in breast cancer · n=149

    Reason given: The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.

  • NCT02119676Phase 2 · started 2014 · terminated

    Ruxolitinib in crc (colorectal cancer) · n=396

    Reason given: Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.

  • NCT02117479Phase 3 · started 2014 · terminated

    Ruxolitinib in pancreatic cancer · n=321

    Reason given: The study was terminated early based on the results of the planned interim analysis.

  • NCT02119650Phase 2 · started 2014 · terminated

    Ruxolitinib in nsclc (non-small cell lung carcinoma) · n=76

    Reason given: The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.

  • NCT02093429Phase 1/2 · started 2014 · terminated

    INCB047986 in mds (myelodysplastic syndrome) · n=6

    Reason given: Business decision.

  • NCT01685255Phase 2 · started 2012 · terminated

    Epacadostat in ovarian cancer · n=83

    Reason given: Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.

  • NCT01604889Phase 1/2 · started 2012 · terminated

    Epacadostat in melanoma · n=50

    Reason given: Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued.

  • NCT01254136Phase 1/2 · started 2010 · terminated

    INCB007839 300mg BID in breast cancer · n=20

    Reason given: Incyte has suspended development of the compound.

  • NCT00726232Phase 2 · started 2008 · terminated

    Ruxolitinib in myeloproliferative neoplasm (mpn) · n=73

    Reason given: Termination of the clinical trial by sponsor.

  • NCT00698789Phase 2 · started 2008 · terminated

    INCB019602 in type 2 diabetes · n=48

    Reason given: Study ended after diabetes development plan review. .

  • NCT00638378Phase 2 · started 2008 · terminated

    Ruxolitinib in prostate cancer · n=22

    Reason given: According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.

  • NCT00864175Phase 1/2 · started 2007 · terminated

    INCB007839 in breast cancer · n=68

    Reason given: Incyte suspended development of the compound.

  • DECLAREPhase 2 · started 2006 · terminated

    Dexelvucitabine in hiv infections · n=250

    Reason given: Development program ended due to inability to pair with other cytidine analogs and higher risk of hyperlipasemia when not used with 3TC/FTC.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.